Chamber and committees

Work is ongoing to ensure the vaccine status of those who volunteered for clinical trials in Scotland is correctly presented on the vaccine database. A letter confirming their involvement in the trials is being issued to those who participated. Any participant who has not yet received a letter should contact their respective research team. The letter can be used for domestic purposes as proof of trial status. However, it’s important to note that we have no plans at present to make vaccine certification a requirement of access to services in Scotland.

The Scottish Government works with the Scottish Environment Protection Agency (SEPA), NatureScot, fisheries boards and trusts, and other stakeholders to protect the natural environment and wildlife from water shortages.

Our River Basin Management Plans identify areas in Scotland already impacted by abstractions and set out objectives to improve those watercourses. SEPA licences and regulates abstractions to ensure that water use does not exceed the available capacity. At times of water scarcity, SEPA has the powers to temporarily stop abstraction, to protect the environment.

The National Water Scarcity Plan sets out how SEPA and other key stakeholders will prepare and respond to water shortages. SEPA works closely with NatureScot and other environmental organisations to provide advice and information on water scarcity so they can act to protect wildlife.

The following data was collected via energy performance certificates (EPCs) submitted for all new build completions in Scotland since 2016. This indicative data is based on analysis of new build EPC records lodged on the EPC register between Q1 2016 and Q4 2020. A total of 92,900 EPC records were analysed.

Numbers in the tables have been rounded to the nearest ten. This is the best currently available data:

Details of the grants awarded by Scottish Government through the Forestry Grant Scheme is shown in the following table:

Government budgets contribute to alleviating the climate emergency through a range of investments, including spend that reduces greenhouse gas emissions towards net zero, spend that delivers emissions reductions through a fair and just transition, and spend focussed on adapting to the effects of climate change.

The 2021-22 Budget increased low carbon capital investment across government to over £1.9 billion, comprising 36% of overall capital spend. This proportion has risen from 29% in 2018-19, when reporting began. In March, following budget negotiations, the Cabinet Secretary for Finance committed to a further £40 million in capital investment for active travel and energy efficiency initiatives that align with our green recovery and net zero ambitions. These figures that we track on low carbon capital investment, as mentioned above, provide only a partial picture of the wide range of investments across all government spend that contributes towards alleviating the climate emergency.

Some of our key commitments on climate change in this budget include increasing our Heat in Buildings investment by £30 million to £213.4 million; increasing forestry investment by £26.9 million to £121.2 million; committing £40 million for our Agricultural Transformation Fund to assist the sector in reducing greenhouse gas emissions; and committing the first £165 million of our £2 billion Low Carbon Fund, including: £14 million for the Green Jobs Fund, £25 million for bus priority infrastructure and £15 million for zero emissions buses.

It is not possible to accurately quantify the future associated with COVID-19 related health problems at this time, as we are still in the midst of the pandemic. Some of these impacts may not be tangible immediately but are likely to become more evident over time.

We need a better understanding of the frequency, nature and impact of health complications caused by COVID before an assessment can be made of future costs. This includes the cost of providing support for people with long COVID.

The Scottish Government has invested £2.5 million funding for nine Scottish-led research projects relating to the long-term effects of COVID-19. We continue to engage with NHS Boards to identify their support needs in relation to delivering care and support to people with long COVID.

I refer the member to the question S6W-01283 which is available on the Parliament's website, the search facility for which can be found at: http://www.parliament.scot/parliamentarybusiness/28877.aspx

All young people 16 to 17 years of age are now being offered the coronavirus (COVID-19) vaccination in Scotland. In line with the latest advice from the Joint Committee on Vaccination and Immunisation (JCVI), they will be offered a first dose of the Pfizer-BioNTech vaccine. People who are 16 or 17 in mainland Scotland will be invited to register their interest through the online portal at NHS Inform, and will then be sent an appointment via SMS or email. Eligible young people in Shetland, Orkney and Western Isles will be contacted by their health board and invited to attend clinics.

Drop-in clinics are available for 16 to 17-years-olds. Anyone who doesn’t register an interest or attend a drop-in clinic, will be sent an appointment invitation through the post.

I refer the member to the answer to question S6W-01283 on
‎ 16 August 2021. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers

The Scottish Government follows the Joint Committee on Vaccination and Immunisation (JCVI) Guidance in developing guidance as the vaccination programme makes progress towards increasing levels of COVID-19 immunity in the population. Current JCVI advice remains that the single greatest risk of mortality and severe disease from COVID-19 is increasing age and COVID-19 risk increases exponentially with age.

Following the recent JCVI advice, young people aged 12 to 15 with severe neuro-disabilities, Down’s Syndrome, immunosuppression and multiple or severe learning disabilities, as well as people who are household contacts of individuals who are immunosuppressed, will be eligible for vaccination soon. The JCVI is not currently advising routine vaccination of children outside of these groups, based on the current evidence.

All young people 16 to 17 years of age will now be offered the coronavirus (COVID-19) vaccination in Scotland. In line with the latest advice from the JCVI, they will be offered a first dose of the Pfizer-BioNTech vaccine. People who are 16 or 17 in mainland Scotland will be invited to register their interest through the online portal at NHS Inform, and will then be sent an appointment via SMS or email. Eligible young people in Shetland, Orkney and Western Isles will be contacted by their health board and invited to attend clinics.

Drop-in clinics are available for 16 to 17-years-olds. Anyone who doesn’t register an interest or attend a drop-in clinic, will be sent an appointment invitation through the post. It is expected that everyone in this age group will have been offered a vaccination appointment by the end of September.

The advice to protect against the risks of contracting COVID-19 or developing any associated ‘Long COVID’ signs and symptoms, remain the same for those who are vaccinated as those unable to receive vaccination for medical reasons. There is further detailed advice available, which is continuously updated in line with protection levels advice, for those who have been shielding for health reasons published here: Coronavirus (COVID-19): shielding advice and support - gov.scot (www.gov.scot) .

Like all medicines, no vaccine is completely effective, but we do know the vaccination of a high proportion of the population will assist in reducing symptomatic disease and transmission. As the vaccination programme progresses, the Scottish Government advises everyone to follow the protection level rules set for each Local Authority area, as well as to follow general public health guidance issued on non-pharmaceutical measures which help to reduce the spread of COVID-19.

In addition to the individual level of protection against severe disease or hospitalisation afforded by vaccination, a further benefit of the vaccination programme is to assist in developing widespread community immunity and thereby reduce the force of transmission and viral reproduction rate, controlling the prevalence of COVID-19.

Research by Public Health England (PHE), which monitors vaccine efficacy within the UK, shows that those who became infected 3 weeks after receiving one dose of the Pfizer-BioNTech or AstraZeneca vaccine were between 38% and 49% less likely to pass the virus on to their household contacts than those who were unvaccinated. Protection was seen from around 14 days after vaccination, with similar levels of protection regardless of age of cases or contacts. Data is published here: One dose of COVID-19 vaccine can cut household transmission by up to half - GOV.UK (www.gov.uk) . Further research into the COVID-19 vaccines’ impacts on transmission is underway.

The inoculation of a large proportion of the population will help to provide a degree of ‘passive protection’ in the community for those who cannot receive vaccination for medical reasons and those who may develop a weaker immune response to vaccination due to old age, immunosuppression or illness.